Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth
Menée in vitro, in vivo et à partir d'échantillons tumoraux prélevés sur des patients atteints de diverses formes de leucémie, cette étude met en évidence le rôle joué par une enzyme, PGAM1, dans les processus de glycolyse et de biosynthèse pour favoriser la croissance tumorale
It is unclear how cancer cells coordinate glycolysis and biosynthesis to support rapidly growing tumors. We found that the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1), commonly upregulated in human cancers due to loss of TP53, contributes to biosynthesis regulation in part by controlling intracellular levels of its substrate, 3-phosphoglycerate (3-PG), and product, 2-phosphoglycerate (2-PG). 3-PG binds to and inhibits 6-phosphogluconate dehydrogenase in the oxidative pentose phosphate pathway (PPP), while 2-PG activates 3-phosphoglycerate dehydrogenase to provide feedback control of 3-PG levels. Inhibition of PGAM1 by shRNA or a small molecule inhibitor PGMI-004A results in increased 3-PG and decreased 2-PG levels in cancer cells, leading to significantly decreased glycolysis, PPP flux and biosynthesis, as well as attenuated cell proliferation and tumor growth.
º PGAM1 controls 3-PG and 2-PG levels to coordinate glycolysis and biosynthesis
º 3-PG binds to and inhibits 6PGD in the oxidative PPP
º 2-PG potentiates PHGDH to provide feedback control of 3-PG levels
º PGAM1 is a promising anticancer target
Cancer cell , résumé, 2011